BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37544974)

  • 1. Ligand-based drug design of quinazolin-4(3H)-ones as breast cancer inhibitors using QSAR modeling, molecular docking, and pharmacological profiling.
    Abdullahi SH; Uzairu A; Shallangwa GA; Uba S; Umar AB
    J Egypt Natl Canc Inst; 2023 Aug; 35(1):24. PubMed ID: 37544974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic profiling of quinazoline-4(3H)-one analogs as EGFR inhibitors: 3D-QSAR modeling, molecular docking studies and the design of therapeutic agents.
    Abdullahi SH; Uzairu A; Shallangwa GA; Uba S; Umar AB
    J Taibah Univ Med Sci; 2023 Oct; 18(5):1018-1029. PubMed ID: 36959916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
    Kale MA; Sonwane GM
    Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies.
    Bhujbal SP; He W; Hah JM
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, Molecular Docking, and 2D-QSAR Modeling of Quinoxaline Derivatives as Potent Anticancer Agents against Triple-negative Breast Cancer.
    Kaushal T; Khan S; Fatima K; Luqman S; Khan F; Negi AS
    Curr Top Med Chem; 2022; 22(10):855-867. PubMed ID: 35331094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
    Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
    Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QSAR Study, Molecular Docking and Molecular Dynamic Simulation of Aurora Kinase Inhibitors Derived from Imidazo[4,5-
    Tian YY; Tong JB; Liu Y; Tian Y
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
    Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
    Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potent aldose reductase inhibitors as antidiabetic (Anti-hyperglycemic) agents using QSAR based virtual Screening, molecular Docking, MD simulation and MMGBSA approaches.
    Bakal RL; Jawarkar RD; Manwar JV; Jaiswal MS; Ghosh A; Gandhi A; Zaki MEA; Al-Hussain S; Samad A; Masand VH; Mukerjee N; Nasir Abbas Bukhari S; Sharma P; Lewaa I
    Saudi Pharm J; 2022 Jun; 30(6):693-710. PubMed ID: 35812153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of Novel Chemotherapeutic Agents Targeting Checkpoint Kinase 1 Using 3D-QSAR Modeling and Molecular Docking Methods.
    Balupuri A; Balasubramanian PK; Cho SJ
    Curr Comput Aided Drug Des; 2016; 12(4):302-313. PubMed ID: 27585602
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Shirvani P; Fassihi A
    J Biomol Struct Dyn; 2022 Aug; 40(13):5965-5982. PubMed ID: 33475043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QSAR, molecular docking, design, and pharmacokinetic analysis of 2-(4-fluorophenyl) imidazol-5-ones as anti-breast cancer drug compounds against MCF-7 cell line.
    Lawal HA; Uzairu A; Uba S
    J Bioenerg Biomembr; 2020 Dec; 52(6):475-494. PubMed ID: 33247393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Influenza PA
    Zhang C; Xiang J; Xie Q; Zhao J; Zhang H; Huang E; Shaw P; Liu X; Hu C
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR.
    El-Hassab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2020 Sep; 38(15):4521-4535. PubMed ID: 31647392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering the Interactions of Bioactive Compounds in Selected Traditional Medicinal Plants against Alzheimer's Diseases via Pharmacophore Modeling, Auto-QSAR, and Molecular Docking Approaches.
    Ojo OA; Ojo AB; Okolie C; Nwakama MC; Iyobhebhe M; Evbuomwan IO; Nwonuma CO; Maimako RF; Adegboyega AE; Taiwo OA; Alsharif KF; Batiha GE
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33915968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis,
    Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
    Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.
    Abbasi M; Sadeghi-Aliabadi H; Amanlou M
    Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Combined Approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and In silico ADME/Tox Prediction of 4-Arylthio & 4-Aryloxy-3- Iodopyridine-2(1H)-one Analogs to Identify Potential Reverse Transcriptase Inhibitor: Anti-HIV Agents.
    Panigrahi D; Mishra A; Sahu SK; Azam MA; Vyshaag CM
    Med Chem; 2022; 18(1):51-87. PubMed ID: 33319692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D-QSAR and scaffold hopping based designing of benzo[d]ox-azol-2(3H)-one and 2-oxazolo[4,5-b]pyridin-2(3H)-one derivatives as selective aldehyde dehydrogenase 1A1 inhibitors: Synthesis and biological evaluation.
    Verma H; Narendra G; Raju B; Kumar M; Jain SK; Tung GK; Singh PK; Silakari O
    Arch Pharm (Weinheim); 2022 Sep; 355(9):e2200108. PubMed ID: 35618489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.